Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Prostatic Neoplasms 2Breast Neoplasms 2Waldenstrom Macroglobulinemia 1Somatostatinoma 1Recurrence 1Pituitary Neoplasms 1Optic Nerve Glioma 1Lymphoma, Mantle-Cell 1Growth Hormone-Secreting Pituitary Adenoma 1Colonic Neoplasms 1Carcinoma, Neuroendocrine 1Carcinoma, Merkel Cell 1Carcinoma, Islet Cell 1

Interventions

Temozolomide 2gallium Ga 68 dotatate 1antineoplaston AS 2-1 1antineoplaston A10 1Radiotherapy 1N(alpha)-(4-amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L-ornithine 1Magnetic Resonance Spectroscopy 1Drug Therapy 12-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Optic Nerve Glioma × antineoplaston A10 × Clear all
NCT01260103 2017-07-26

Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma

Burzynski Research Institute

Phase 3 Withdrawn
CNS

Recurrence, Optic Nerve Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡